A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

Naji NS, Ahmedna T, Zeng X, An Y, Hemani Y, Perkins B, Thompson Z, Nichakawade TD, Wang Y, Lee BS, Watson E, Chatzilygeroudi T, Luo L, Paun B, Klausner M, Supeanu T, Gojo I, Ghiaur G, DeZern AE, Levis MJ, Resar L, Jones RJ, Peske JD, Karanika S, Paul S, Karantanos T

Open source

DOI: 10.1182/bloodadvances.2025019380
Published: 2026 Aug 25
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025019380,
  title = {A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.},
  author = {Naji NS and Ahmedna T and Zeng X and An Y and Hemani Y and Perkins B and Thompson Z and Nichakawade TD and Wang Y and Lee BS and Watson E and Chatzilygeroudi T and Luo L and Paun B and Klausner M and Supeanu T and Gojo I and Ghiaur G and DeZern AE and Levis MJ and Resar L and Jones RJ and Peske JD and Karanika S and Paul S and Karantanos T},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025019380},
  url = {https://doi.org/10.1182/bloodadvances.2025019380}
}

RIS

TY  - JOUR
TI  - A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.
AU  - Naji NS
AU  - Ahmedna T
AU  - Zeng X
AU  - An Y
AU  - Hemani Y
AU  - Perkins B
AU  - Thompson Z
AU  - Nichakawade TD
AU  - Wang Y
AU  - Lee BS
AU  - Watson E
AU  - Chatzilygeroudi T
AU  - Luo L
AU  - Paun B
AU  - Klausner M
AU  - Supeanu T
AU  - Gojo I
AU  - Ghiaur G
AU  - DeZern AE
AU  - Levis MJ
AU  - Resar L
AU  - Jones RJ
AU  - Peske JD
AU  - Karanika S
AU  - Paul S
AU  - Karantanos T
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025019380
UR  - https://doi.org/10.1182/bloodadvances.2025019380
ER  -

APA

NS, N., T, A., X, Z., Y, A., Y, H., B, P., Z, T., TD, N., Y, W., BS, L., E, W., T, C., L, L., B, P., M, K., T, S., I, G., G, G., AE, D., MJ, L., L, R., RJ, J., JD, P., S, K., S, P., & T, K. (2026). A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.. Blood advances. https://doi.org/10.1182/bloodadvances.2025019380

Source records

pubmed · retrieved 2026-11-10T14:17:42.828Z